The European Medicines Agency has granted Eli Lilly and Co.’s enzastaurin drug “orphan” status—a decade of marketing exclusivity for drugs aimed at serious, rare illnesses.
As a result, the
Separately, Bloomberg reports that Lilly plans to spend $150 million to triple the size of its research center in
Please enable JavaScript to view this content.